Urothelial Carcinoma — Trials

Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

623 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 236
Recruiting: 118
Ph III recruiting: 14
Growth YoY: +37.5%
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (99)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04688931	A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ATLAS)	terminated	Phase 3	282	UroGen Pharma Ltd.INDUSTRY	10	Jun 6, 2024	clinicaltrials
NCT04197986	Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations(PROOF302)	terminated	Phase 3	39	QED Therapeutics, a BridgeBio companyINDUSTRY